We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-1.50 | -1.15% | 129.00 | 127.00 | 131.00 | 130.50 | 129.00 | 130.50 | 244,243 | 14:53:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 150.00 | 108.97M |
TIDMDXRX
RNS Number : 0347A
Diaceutics PLC
19 May 2023
19 May 2023
Diaceutics PLC
("Diaceutics" or "the Company")
Issue of Share Options/PDMR Shareholdings
Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, announces the issue of 1,276,707 share options over ordinary shares of GBP0.002 each in the Company ("Share Options") to certain directors, members of the Company's senior management team and other key staff, pursuant to the Company's Employee Share Option Plan ("ESOP"). These awards are made in accordance with the Company's long term incentive plan as detailed in the Company's Annual Report.
Share Options were granted as follows:
Name Number of Total no. of % of existing Effective Share Options ordinary shares issued share Grant date granted under option post capital grant Peter Keeling, CEO 102,468 435,313 0.52% 18 May 2023 -------------- ------------------ ------------- ----------- Nick Roberts, CFO 67,034 158,872 0.19% 18 May 2023 -------------- ------------------ ------------- ----------- Ryan Keeling, CIO 93,407 409,851 0.49% 18 May 2023 -------------- ------------------ ------------- ----------- Julie Browne, COO and PDMR 67,109 169,047 0.20% 18 May 2023 -------------- ------------------ ------------- ----------- Jordan Clark, CCO and PDMR 65,245 115,740 0.14% 18 May 2023 -------------- ------------------ ------------- ----------- Susanne Munksted, CPO and PDMR 68,834 249,199 0.30% 18 May 2023 -------------- ------------------ ------------- ----------- Other employees (43 persons) 812,610 1,675,537 1.98% 18 May 2023 -------------- ------------------ ------------- -----------
The Share Options vest on a sliding scale up to 100%, after three years from the date of grant (the "Performance Period"), subject to the satisfaction of certain performance criteria. The performance criteria are based upon the growth in the proportion of subscription revenue and Total Shareholder Return ("TSR") during the Performance Period. The growth in TSR will be measured against a base share price of 103.97p, being the average mid-market closing share price in the three days prior to 18 May 2023. The exercise price of the Share Options is GBP0.002 per share which equates to the nominal value of the ordinary shares.
Following this grant, the total number of share options outstanding in the Company is 3,826,487 representing approximately 4.52% of its current issued share capital of 84,461,386.
Enquiries:
Diaceutics PLC Peter Keeling, Chief Executive Officer Via Alma PR Nick Roberts, Chief Financial Officer Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600 Ben Maddison, Nick Harland, Nick Adams Alma PR Tel: +44(0)20 3405 0205 Caroline Forde, Kieran Breheny, Matthew Young diaceutics@almapr.co.uk
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by the proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real--world healthcare data insights, advisory services and innovative platform enabled solutions.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------- a. Name Peter Keeling ----------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------- a. Position/Status Chief Executive Officer, Director ------------------------------------- ----------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of 0.2 the financial p each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- -------------------------- Exercise price of 0.2p per share 102,468 ---------------------------------------------------------------------- --------------- e. Date of the transaction 18 May 2023 ------------------------------------- ----------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------- a. Name Nick Roberts ----------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------- a. Position/Status Chief Finance Officer, Director ------------------------------------- ----------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of 0.2 the financial p each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- -------------------------- Exercise price of 0.2p per share 67,034 ---------------------------------------------------------------------- --------------- e. Date of the transaction 18 May 2023 ------------------------------------- ----------------------------------------------- f. Place of the transaction Outside a trading venue
------------------------------------- ----------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------- a. Name Ryan Keeling ----------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------- a. Position/Status Chief Innovation Officer , Director ------------------------------------- ----------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of 0.2 the financial p each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- -------------------------- Exercise price of 0.2p per share 93,407 ---------------------------------------------------------------------- --------------- e. Date of the transaction 18 May 2023 ------------------------------------- ----------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------- a. Name Julie Browne ----------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------- a. Position/Status Chief Operations Officer and PDMR ------------------------------------- ----------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of 0.2 the financial p each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- -------------------------- Exercise price of 0.2p per share 67,109 ---------------------------------------------------------------------- --------------- e. Date of the transaction 18 May 2023 ------------------------------------- ----------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- -------------------------------------------------------------------------------------- a. Name Jordan Clark ----------------------------------------------- 2 Reason for notification ------------------------------------- ----------------------------------------------- a. Position/Status Chief Commercial Officer and PDMR ------------------------------------- ----------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81 ------------------------------------- ----------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- -------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of 0.2 the financial p each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ----------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ----------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- -------------------------- Exercise price of 0.2p per share 65,245 ---------------------------------------------------------------------- --------------- e. Date of the transaction 18 May 2023 ------------------------------------- ----------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- ----------------------------------------------- Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ----- ---------------------------------------------------------------------------------------- a. Name Susanne Munksted ------------------------------------------------- 2 Reason for notification ------------------------------------- ------------------------------------------------- a. Position/Status Chief Precision Medicine Officer and PDMR ------------------------------------- ------------------------------------------------- b. Initial notification/ Initial Amendment ------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------- b. LEI 213800VEWQBB39ZB8J81
------------------------------------- ------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ----- ---------------------------------------------------------------------------------------- a. Description of Options over new ordinary shares of 0.2 the financial p each instrument, type of instrument ISIN: GB00BJQTGV64 Identification Code ------------------------------------- ------------------------------------------------- b. Nature of the Grant of share options transaction ------------------------------------- ------------------------------------------------- c. Price(s) and volume(s) Price(s) Volume(s) ------------------------------------- --------------------------- Exercise price of 0.2p per share 68,834 ----------------------------------------------------------------------- ---------------- e. Date of the transaction 18 May 2023 ------------------------------------- ------------------------------------------------- f. Place of the transaction Outside a trading venue ------------------------------------- -------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHKKLBFXELFBBZ
(END) Dow Jones Newswires
May 19, 2023 05:16 ET (09:16 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions